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Background: Burkholderia multivorans poses a serious health threat to Cystic Fibrosis patients due to innate resistance to multiple
antibiotics and acquisition of resistance to a range of antibiotics due to the frequent use of antibiotics to treat chronic infections.
Monitoring antibiotic susceptibility is crucial to managing patient care. We identiﬁed the rapid emergence of a ceftazidime-resistant
strain in a single patient within four days during a hospitalization for treatment of an exacerbation.
Methods: B. multivorans was isolated from expectorated sputum samples using Burkholderia cepacia selective agar. A macrodilution assay was
performed on all isolates to determine the minimum inhibitory concentration of ceftazidime. Approximately 4000 colonies were scored to identify the
percent of ceftazidime-resistant colonies. Extracted DNA was used to determine the total bacterial counts and abundance of B. multivorans using
quantitative PCR.
Results: An increase from no detectable B. multivorans ceftazidime-resistant colonies to over 75% of all colonies tested occurred
within a four-day period. The resistant population remained dominant in 6 of the 8 samples in the following 17 months of the study.
qPCR revealed an association between change in the percent of resistant colonies and abundance of B. multivorans, but not of total
bacteria. No association was found between the acquisition of resistance to ceftazidime and other antibiotics commonly used to treat
B. multivorans infections.
Conclusions: The rapid emergence of a ceftazidime-resistant by B. multivorans strain occurred during a hospitalization while under selective
pressure of antibiotics. The resistant strain maintained dominance in the B. multivorans population which resulted in an overall decline in a patient
health and treatment efﬁcacy.
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Burkholderia cepacia complex (Bcc) bacteria pose a
serious health threat to Cystic Fibrosis (CF) patients due
to the innate resistance to multiple antibiotics and ability to
adapt to adverse environmental conditions through multiple⁎ Corresponding author at: Department of Biology, University of North Carolina
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1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.01.009mechanisms [1,2]. Bcc bacteria infect approximately 2.5%
of CF patients in the US and Burkholderia cenocepacia,
B. cepacia and Burkholderia multivorans have been associated
with a form of septicemia known as “cepacia syndrome” [3,4].
While studies have described the adaptive responses of
Pseudomonas aeruginosa, equivalent studies that examine the
adaption of Bcc species in the CF lung are lacking [5]. Here we
document in vivo the emergence of a resistant strain of
B. multivorans during in-hospital antibiotic treatment for a
pulmonary exacerbation (PE) and the decreased response to
subsequent antibiotic treatment.by Elsevier B.V. All rights reserved.
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2.1. Patient and sample collection
A 30-year-old male diagnosed with CF at two weeks of age
was hospitalized on January 4, 2010 for a course of intravenous
antibiotics due to an acute worsening of signs and symptoms
consistent with a PE. Approximately four weeks later, the patient
was readmitted to the hospital with symptoms of a PE. Sputum
culture results from the second admission revealed the presence
of ceftazidime-resistant B. multivorans.
Expectorated sputum samples were obtained from the CF
patient twice weekly for a period of almost three years (IRB
Protocol Approval # 11-12-36). Samples were collected each
morning by the patient, placed on ice during transport to the lab,
and then stored at −80 °C. Single colonies of B. multivorans
were obtained from sputum enriched in Burkholderia cepacia
selective broth (BCSB) at 37 °C for 48 h by spreading diluents
onto B. cepacia selective agar (BCSA) plates [6]. A single colony
from the BCSA plate was used to inoculate 2 mL of LB broth and
incubated for 48 h at 37 °C to be used for antibiotic susceptibility
testing.
2.2. B. multivorans ceftazidime-resistance determination
Ceftazidime-resistant colonies were identified by transferring
single colonies from BCSA onto LB agar with and without
15 μg/mL ceftazidime (MIC determined using a standard
macrodilution tube method [7]) and scoring for growth after
48 h at 37 °C. Ceftazidime-resistance was measured in isolates
from sputum samples spanning a 26-month period beginning
March 2009, two months following hospitalization for PE
treatment in January 2010 and ending May 2011, 18 months
after hospitalization. Percent resistance was measured by replica
plating approximately 200–400 colonies isolated from each of 13
sputum samples onto LB±15 μg/mL ceftazidime, and scoring
for growth following incubation at 37 °C for 48 h.
2.3. Sample processing
Each sputum sample was mixed with a 1:3 ratio of sputum
to a 0.1% dithiothreitol solution and incubated at 37 °C for 1 h
followed by mechanical homogenization for 1 min using a
micro blender. Propidium monoazide (Biotium, Hayward, CA)
was then added to a final concentration of 50 μmol/mL, and
DNA-cross linking was induced using a 400-watt halogen
light source [8]. DNA was extracted using the IT 1-2-3
VIBE Sample Purification Kit (Idaho Technologies, Salt Lake
City, UT).
2.4. qPCR methods
qPCR using Perfecta SYBR Green FastMix Reagent Low
ROX (Quanta Biosciences, Gaithersburg, MD) was performed
using the ABI 7500 Fast Real-Time PCR System (Applied
Biosystems, Carlsbad, CA) with a detailed protocol described
in [9]. Universal primers [10] targeting a 16S rDNA fragmentof 466 bp were used to measure total bacterial abundance.
Bcc-specific primers [11] targeting members of the B. cepacia
complex generated a fragment of 333 bp. Standard curves were
created using 10-fold dilutions of amplicons generated using
B. multivorans DNA as a template.
2.5. MLST analysis
Multilocus sequence typing (MLST) was performed in silico to
determine the relatedness of isolates examined during the study
period. Concatenated sequences of B. multivorans DNA collected
as part of an ongoing whole-genome Illumina sequencing analysis
were used to determine the sequence identity of the seven
housekeeping genes used to differentiate strains according to
Baldwin et al. [12]. ClustalW was used to align the sequence of
each MLST locus and determine the similarity of alleles between
isolates [13]. To obtain an allelic profile and clonal complex
designation, PubMLST was used to align each locus to
the B. cepacia complex database. These will be available at
the B. cepacia complex database (http://pubmlst.org/bcc/). Both
PubMLST and NCBI BLAST were used to align the recA gene
and a DNA sequence spanning the V1–V3 regions of the 16S
rRNA gene, respectively, to verify the species identity [14].
3. Results
In vivo acquisition of ceftazidime-resistant B. multivoranswas
detected by examining changes in the percentage of resistant
colonies. In the four sputum samples collected before January 14,
2010, no ceftazidime-resistant B. multivorans colonies were
detected. In the January 14, 2010 sample, 78% of colonies were
resistant. This percentage ranged from 69% to 97% in six of the
subsequent eight samples collected over a 26-month period
(Fig. 1). A decrease in the percentage of resistant colonies to 1%
and 7% in two sputum samples collected five months after the
resistant strain of B. multivorans was first detected and did not
correlate with the administration of antibiotics or patient health.
To determine if the percent resistance was connected to the
changes in total bacterial abundance, qPCR was used to measure
abundance of all bacteria and B. multivorans from all sputum
samples. The results (Fig. 1) indicate that there was a correlation
between abundance of B. multivorans and percent resistance but
not for total bacterial counts.
The change in abundance resulting from antibiotic treatment
was compared for the three exacerbations that occurred prior to
the detection of ceftazidime resistance (32 samples) with four
subsequent exacerbations (34 samples). There was a statistically
significant (Student's t-test) decrease in abundance caused by
non-ceftazidime antibiotics for the first three exacerbations but
not for the four post-acquisition exacerbations (Fig. 2).
Appearance of ceftazidime-resistant Bcc could occur due to
the acquisition of a new Bcc strain or selection of an existing Bcc
strain. To determine if the ceftazidime-resistant and -sensitive
strains are clonal, the sequences of five of the seven genes
used for MLST analysis were compared and found to be 100%
identical for 12 isolates (Table 1). The only exception was gyrB
which was 96% identical for the AS130A, AS130B, and AS131
Fig. 1. Total bacterial abundance, Burkholderia-specific abundance, and percent of ceftazidime- resistant Burkholderia multivorans colonies measured from sputum
samples collected during the 26-month sampling period. DNA isolated from sputum samples, as described in the addendum, was subjected to qPCR using
Burkholderia cepacia complex-specific 16S rDNA primers12. The abundance values, expressed as copy number, represent the averages of three replicates. The dates
of the study period are given.
Fig. 2. Effect of antibiotics on abundance of B. multivorans in sputum samples
before and after treatment. Antibiotics given prior to the acquisition of the
ceftazidime-resistant strain (A) caused a significant decrease (P=.01 by Student’s
t-test) in abundance during treatment for an exacerbation. Antibiotics given to treat
an exacerbation that occurred after the acquisition of the ceftazidime-resistant strain
(B) showed no significant change (P=.63 by Student’s t-test) in abundance during
treatment.
814 J.R. Stokell et al. / Journal of Cystic Fibrosis 12 (2013) 812–816isolates due to a partial lack of sequence coverage in the first 41
nucleotides. The trpB locus for each isolate was not usable for
alignment due to multiple N's within the sequence generated
during assembly (data not shown). An exact allele match was
found for six loci when compared to the PubMLST database
while the trpB locus showed a near match to two different alleles
(Table 1). All isolates shared 100% identity in six alleles with each
allele corresponding to a B. multivorans isolate in the PubMLST
database. BLAST showed a sequence similarity of 99% in the
V1–V3 regions of the 16S rRNA gene when compared to the
B. multivorans ATCC 17616 reference strain and an exact match
of the recA gene to B. multivorans in the PubMLST database was
found for all isolates, confirming their identity as B. multivorans
(Table 1).
In vitro testing of four ceftazidime-sensitive and four
ceftazidime-resistant isolates for resistance to two other antibiotics
commonly used to treat B. multivorans infections, trimethoprim/
sulfamethoxazole (TMP–SMZ) and minocycline, showed no
significant difference and was consistent with the result of clinical
susceptibility tests performed during the sampling period (data not
shown). No other beta-lactam, such as meropenem, was tested
since B. multivoranswas shown to be consistently resistant to this
carbapenem in clinical analyses of isolates from sputum samples
collected prior to and during the study period; indicating that the
acquisition of ceftazidime resistance occurred independently of
treatment with any other antibiotic.
4. Discussion
Here we document a dramatic in vivo change in the resistance
profile of B. multivorans, a major CF pathogen. Clinical analysis
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815J.R. Stokell et al. / Journal of Cystic Fibrosis 12 (2013) 812–816of B. multivorans showed a change in the susceptibility profile
from sensitive to intermediate ceftazidime resistance in a period
of one month (data not shown). We were able to narrow that
window to a period of four days, suggesting that administration
of the antibiotic caused the increase in in vivo resistance.
The increase in percent resistance occurred without a change in the
total B. multivorans abundance. Although phenotypic variability
has been shown to exist within multiple isolates from the same
patient in a given sputum sample [15], repeated testing of every
isolate collected during the 26-month period for antibiotic
susceptibility and MIC indicates that the phenotype is stable.
While the lower percentage of resistant isolates shown in Fig. 1
cannot be explained at this time, the stability of antibiotic resistance
profile for each isolate from every time point indicates that this
observation reflects a change in the population profile (ratio
of ceftazidime-resistant/sensitive) and not a chance observation.
A transient decrease in the percentage of B. multivorans that was
ceftazidime-resistant (Fig. 1) may reflect normal changes that occur
in the microbial community, though this model would differ from
the current consensus on the stability of the lung microbiome [16].
Alternatively, this phenomenon may have occurred due to an
unidentified environmental change. And although spatial hetero-
geneity of microbial communities has been observed in ex-plant
and post mortem CF lungs, we attempted to resolve some of this
potential variability by using identical methods for obtaining each
sputum sample [17].
Bcc is intrinsically resistant to multiple antibiotics including
β-lactams, aminoglycosides, and fluoroquinolones [18]. Acqui-
sition of resistance to one of the few antibiotics known to be
effective against Bcc such as ceftazidime is suggested to arise
from antibiotic stress, however, the exact mechanism has yet to be
elucidated [2,19]. Our observation of no recognizable pattern of
resistance to TMP–SMZ or minocycline associated with the
ceftazidime-resistant B. multivorans strain suggests that resistance
is not due to a typical multi-drug resistant mechanism as seen in
previous Bcc studies [20]. A statistically significant decrease in
abundance of B. multivorans, but not of total bacteria, caused
by non-ceftazidime antibiotics for the first three exacerbations
(Fig. 2) suggests that the acquisition of resistance affected
the response of B. multivorans to treatment with more than
ceftazidime and a measurable change in the phenotype.
Documentation of the acquisition of a change in phenotype
in a given strain requires confirming the identity of the isolates
and that those collected over time are clonal. We were able to
identify each isolate to the species level by aligning the V1–V3
regions of the 16S rRNA gene to a B. multivorans reference
genome and the recA locus to the PubMLST database. EachMLST
locus, included recA, matched an allele that only corresponded to a
B. multivorans isolate in the PubMLST database. The comparison
of MLST loci along with the 99% similarity of the 16S rRNA gene
sequence of the isolates to the B. multivorans ATCC 17616
reference genome indicates that all of the isolates are of the same
species. We characterized the allelic profile of six genes used for
MLST analysis in each of the sequential isolates collected during
the 26-month period and found a near match to three sequence
types (ST), including 198, 417, and 659. A near match for clonal
complex 198 was identified, based on the ST for each isolate,
816 J.R. Stokell et al. / Journal of Cystic Fibrosis 12 (2013) 812–816suggesting that all isolates are clonal. Through MLST analysis,
we were able to determine that ceftazidime resistance is likely due
to in vivo acquisition of resistance.
We have shown that the acquisition of antibiotic resistance can
lead to a decreased reduction in the abundance of B. multivorans
during subsequent antibiotic treatment for exacerbations. While
there is a low expectation of eradicating pathogens in CF due to
complex issues surrounding treatment of persistent bacterial
infections, identifying the emergence of resistant strains impacts
treatment options.
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